Lv4
570 积分 2024-11-01 加入
Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers
9小时前
待确认
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
18天前
已完结
Delayed initial radioiodine therapy related to incomplete response in low‐ to intermediate‐risk differentiated thyroid cancer
28天前
已完结
Statin Use and the Risk of Graves’ Orbitopathy: A Nationwide Population-Based Cohort Study
1个月前
已完结
Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies
1个月前
已完结
Cost-effectiveness of PET and PET/Computed Tomography
2个月前
已完结
FAPIROC: SEQUENTIAL LU-177 FAPI THERAPY AND CHEMOTHERAPY IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER – AN INITIAL CLINICAL EXPERIENCE
2个月前
已关闭
177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
2个月前
已关闭
Significance of Thyroid Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves’ Disease
2个月前
已完结
Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
4个月前
已完结
皖公网安备34019202002308
